Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Src is a nonreceptor tyrosine kinase crucial for osteoclast function.
• Osteoclast-mediated resorption plays a key role in bone remodeling and disease.

Purpose of the Study:

• To investigate if compounds binding to the Src SH2 domain can inhibit Src activity.
• To determine if these compounds reduce osteoclast-mediated bone resorption.

Main Methods:

• In vitro fluorescence polarization assay to assess SH2 domain binding.
• Cell-based assays including mammalian two-hybrid, morphological reversion, and cortactin phosphorylation inhibition.
• Testing of bone-targeting compounds for rabbit osteoclast resorption inhibition.

Main Results:

• Compounds demonstrated in vitro binding to the Src SH2 domain in the nmol/L range.
• Selected compounds inhibited Src activity in multiple cell-based assays.
• Synthesized compounds, designed to bind bone, successfully inhibited osteoclast-mediated resorption.

Conclusions:

• Compounds that bind the Src SH2 domain inhibit Src kinase activity in cellular models.
• Targeting the Src SH2 domain with specific compounds offers a potential strategy to reduce osteoclast-mediated bone resorption.